# Vaccine and Treatment Evaluation Units: Clinical Trial Implementation and Assays to Support a Phase II Influenza Vaccine Trial

> **NIH NIH N01** · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · 2022 · $5,000

## Abstract

This program is comprised of a consortium of individual contracts within academic centers and organizations that provide a ready resource for the design and conduct of clinical trials to evaluate promising products to combat infectious diseases. In general, products will be evaluated in normal healthy populations; however, access to special populations is also available.

## Key facts

- **NIH application ID:** 10709839
- **Project number:** 272201300019I-P00005-27200009-1
- **Recipient organization:** KAISER FOUNDATION HEALTH PLAN OF WASHINGTON
- **Principal Investigator:** LISA JACKSON
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $5,000
- **Award type:** —
- **Project period:** 2017-07-28 → 2023-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10709839

## Citation

> US National Institutes of Health, RePORTER application 10709839, Vaccine and Treatment Evaluation Units: Clinical Trial Implementation and Assays to Support a Phase II Influenza Vaccine Trial (272201300019I-P00005-27200009-1). Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/grant/nih/10709839. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*